PMID- 36214602
OWN - NLM
STAT- MEDLINE
DCOM- 20230105
LR  - 20230111
IS  - 1473-2165 (Electronic)
IS  - 1473-2130 (Linking)
VI  - 21
IP  - 12
DP  - 2022 Dec
TI  - Proton pump inhibitors-related subacute cutaneous lupus erythematosus: Clinical 
      characteristics, management, and outcome.
PG  - 7202-7208
LID - 10.1111/jocd.15450 [doi]
AB  - PURPOSE: Previous knowledge about the association between proton pump inhibitors 
      (PPIs) exposure and subacute cutaneous lupus erythematosus (SCLE) was mainly 
      based on limited case reports or few review studies. We aim to evaluate the 
      clinical characteristics, management, and outcome in patients with PPIs-induced 
      SCLE. METHODS: Case reports and case series from 2000 to December 31, 2021, on 
      SCLE induced by PPIs were collected and retrospectively analyzed. RESULTS: A 
      total of 29 patients (6 male and 23 female) were included from 19 studies, the 
      median age was 61 years (range 19-85), and 65.5% of patients were >/=60 years old. 
      37.9% of patients had the history of autoimmune diseases. The incubation period 
      of PPIs intro to SCLE was 6 weeks for PPI-naive patients and 2 weeks for those 
      re-administration of PPIs. The most common symptoms were annular and polycyclic 
      erythematous (74.1%), rash or maculopapular (48.1%), and scaly plaques (40.7%). 
      Trunk (69.2%), extremities (69.2%), face (26.9%), chest (26.9%), and back (26.9%) 
      were common involved locations. Antinuclear antibodies, anti-Ro/SSA antibodies, 
      and anti-La/SSB antibodies were positive in 24 patients (82.8%), 24 patients 
      (82.8%), and 6 patients (20.7%), respectively. Direct immunofluorescence was 
      positive in 50% of cases. Complete clinical remission (92.6%) was observed 
      (median time: 4 weeks) with discontinuation of PPIs and treatment of oral 
      corticosteroids (61.1%), hydroxychloroquine (44.4%), or topical steroids (16.7%). 
      CONCLUSION: PPIs-related SCLE is a rare adverse reaction based on clinical 
      manifestations associated with immunological abnormalities and suggestive 
      histological findings. PPIs should be suspected when considering possible 
      culprits for drug-related SCLE.
CI  - (c) 2022 Wiley Periodicals LLC.
FAU - Deng, Zhenzhen
AU  - Deng Z
AUID- ORCID: 0000-0003-3045-1710
AD  - Department of Pharmacy, The Third Xiangya Hospital, Central South University, 
      Changsha, China.
FAU - Guo, Aiyuan
AU  - Guo A
AD  - Department of Dermatology, The Third Xiangya Hospital, Central South University, 
      Changsha, China.
FAU - Wu, Cuifang
AU  - Wu C
AD  - Department of Pharmacy, The Third Xiangya Hospital, Central South University, 
      Changsha, China.
FAU - Wang, Chunjiang
AU  - Wang C
AUID- ORCID: 0000-0002-8490-0131
AD  - Department of Pharmacy, The Third Xiangya Hospital, Central South University, 
      Changsha, China.
LA  - eng
GR  - 2021JJ40911/Natural Science Foundation of Hunan Province/
GR  - 2021JJ40911/Natural Science Foundation of Hunan Province/
PT  - Journal Article
DEP - 20221031
PL  - England
TA  - J Cosmet Dermatol
JT  - Journal of cosmetic dermatology
JID - 101130964
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
MH  - Humans
MH  - Male
MH  - Female
MH  - Young Adult
MH  - Adult
MH  - Middle Aged
MH  - Aged
MH  - Aged, 80 and over
MH  - *Proton Pump Inhibitors/adverse effects
MH  - Retrospective Studies
MH  - *Lupus Erythematosus, Cutaneous/chemically induced/diagnosis/drug therapy
MH  - Skin/pathology
MH  - Extremities/pathology
OTO - NOTNLM
OT  - clinical characteristics
OT  - pharmacovigilance
OT  - proton pump inhibitors (PPIs)
OT  - subacute cutaneous lupus erythematosus (SCLE)
EDAT- 2022/10/11 06:00
MHDA- 2023/01/06 06:00
CRDT- 2022/10/10 09:22
PHST- 2022/08/23 00:00 [revised]
PHST- 2022/05/27 00:00 [received]
PHST- 2022/10/06 00:00 [accepted]
PHST- 2022/10/11 06:00 [pubmed]
PHST- 2023/01/06 06:00 [medline]
PHST- 2022/10/10 09:22 [entrez]
AID - 10.1111/jocd.15450 [doi]
PST - ppublish
SO  - J Cosmet Dermatol. 2022 Dec;21(12):7202-7208. doi: 10.1111/jocd.15450. Epub 2022 
      Oct 31.